Altre lingue Gritstone bio, Inc.

Azioni

GRTS

US39868T1051

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 18/04/2024			Variaz. 5gg	Var. 1 gen.
0,7437 ^USD	-0,20%		-19,35%	-63,54%

15/04	Nature Medicine pubblica i risultati intermedi dello studio di fase 1/2 di Gritstone Bio sulla piattaforma di vaccino neoantigene "off-the-shelf" (SLATE)	CI
02/04	I principali ribassisti di mezzogiorno	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of 'Off-the-Shelf' Neoantigen Vaccine Platform	16/04
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)	15/04
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	15/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	12/04
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences	08/04
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024	08/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	05/04
Top Midday Decliners	02/04
Gritstone bio Prices $32.5 Million Public Offering of Stock, Warrants	02/04
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering	02/04
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall	01/04
Gritstone Bio Starts Public Offering; Shares Drop After-Hours	01/04
Gritstone bio Announces Proposed Public Offering	01/04
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)	01/04
Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite	01/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	19/03
Earnings Flash (GRTS) GRITSTONE BIO Posts Q4 Revenue $16.3M	05/03
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates	05/03
Gritstone bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	05/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Gritstone bio, Inc.

Azioni

GRTS

US39868T1051

Altre lingue

Filtri